Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP

Watchlist Manager
Tonix Pharmaceuticals Holding Corp Logo
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
Watchlist
Price: 40.65 USD 5.83% Market Closed
Market Cap: 297.6m USD

Intrinsic Value

TNXP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one TNXP stock under the Base Case scenario is 21.12 USD. Compared to the current market price of 40.65 USD, Tonix Pharmaceuticals Holding Corp is Overvalued by 48%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TNXP Intrinsic Value
21.12 USD
Overvaluation 48%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Tonix Pharmaceuticals Holding Corp

Valuation History Unavailable

Historical valuation for TNXP cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
US
Biotechnology
Market Cap
279.6m USD
IPO
Mar 29, 2010
US
Biotechnology
Market Cap
279.6m USD
IPO
Mar 29, 2010
Price
$false
EPS
$false
Tonix Pharmaceuticals Holding Corp
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about TNXP?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Tonix Pharmaceuticals Holding Corp
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Tonix Pharmaceuticals Holding Corp

Current Assets 149.6m
Cash & Short-Term Investments 131.7m
Receivables 3.5m
Other Current Assets 14.3m
Non-Current Assets 43.3m
PP&E 42.3m
Intangibles 120k
Other Non-Current Assets 910k
Efficiency

Free Cash Flow Analysis
Tonix Pharmaceuticals Holding Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Tonix Pharmaceuticals Holding Corp

Revenue
10m USD
Cost of Revenue
-7m USD
Gross Profit
3m USD
Operating Expenses
-75.4m USD
Operating Income
-72.4m USD
Other Expenses
-59.5m USD
Net Income
-131.9m USD
Fundamental Scores

TNXP Profitability Score
Profitability Due Diligence

Tonix Pharmaceuticals Holding Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive Gross Profit
Negative 1-Year Revenue Growth
24/100
Profitability
Score

Tonix Pharmaceuticals Holding Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

TNXP Solvency Score
Solvency Due Diligence

Tonix Pharmaceuticals Holding Corp's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
49/100
Solvency
Score

Tonix Pharmaceuticals Holding Corp's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TNXP Price Targets Summary
Tonix Pharmaceuticals Holding Corp

There are no price targets for TNXP.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Tonix Pharmaceuticals Holding Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for TNXP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

TNXP Insider Trading
Buy and sell transactions by insiders

TNXP News

Other Videos
What is the Intrinsic Value of one TNXP stock?

The intrinsic value of one TNXP stock under the Base Case scenario is 21.12 USD.

Is TNXP stock undervalued or overvalued?

Compared to the current market price of 40.65 USD, Tonix Pharmaceuticals Holding Corp is Overvalued by 48%.

Back to Top